Diary - News
All news Theranexus announces preliminary results of phase II trial of THN102
Lyon, 27 February 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces the preliminary results of its Phase II trial in narcolepsy patients.